Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,153,768
  • Shares Outstanding, K 110,186
  • Annual Sales, $ 13,117 M
  • Annual Income, $ 3,954 M
  • 60-Month Beta 0.13
  • Price/Sales 10.08
  • Price/Cash Flow 27.71
  • Price/Book 4.69
Trade REGN with:

Options Overview Details

View History
  • Implied Volatility 22.13% ( -0.72%)
  • Historical Volatility 19.82%
  • IV Percentile 27%
  • IV Rank 26.43%
  • IV High 35.23% on 07/30/24
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 1.99
  • Today's Volume 604
  • Volume Avg (30-Day) 772
  • Put/Call OI Ratio 1.23
  • Today's Open Interest 30,767
  • Open Int (30-Day) 32,838

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 10.04
  • Number of Estimates 9
  • High Estimate 11.27
  • Low Estimate 9.28
  • Prior Year 10.17
  • Growth Rate Est. (year over year) -1.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,041.85 +15.24%
on 08/01/24
1,211.20 -0.87%
on 08/27/24
+122.01 (+11.31%)
since 07/26/24
3-Month
952.30 +26.08%
on 05/30/24
1,211.20 -0.87%
on 08/27/24
+215.62 (+21.89%)
since 05/24/24
52-Week
769.19 +56.09%
on 10/27/23
1,211.20 -0.87%
on 08/27/24
+370.29 (+44.59%)
since 08/25/23

Most Recent Stories

More News
This Cathie Wood Stock Can Soar 221%, Says Wall Street

Promising clinical trial results have analysts optimistic about the company’s future.

ARKK : 45.42 (-0.68%)
NTLA : 22.94 (-2.71%)
$SPX : 5,625.80 (+0.16%)
REGN : 1,201.76 (+0.20%)
Is Regeneron Pharmaceuticals Due for a Stock Split?

Would a stock split help lead Regeneron Pharmaceuticals shares higher?

REGN : 1,201.76 (+0.20%)
Regeneron: Q2 Earnings Snapshot

Regeneron: Q2 Earnings Snapshot

REGN : 1,201.76 (+0.20%)
Bull Market Buys: 2 Growth Stocks to Own for the Long Run

These companies are no strangers to beating the market.

LLY : 954.48 (+0.42%)
REGN : 1,201.76 (+0.20%)
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

REGN : 1,201.76 (+0.20%)
$SPX : 5,625.80 (+0.16%)
XBI : 101.07 (-0.62%)
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

Revenue is climbing at these two drug companies -- and the trend should continue.

WMT : 76.13 (+0.13%)
CMG : 56.14 (+2.54%)
NVO : 135.18 (-0.09%)
NVDA : 128.30 (+1.46%)
REGN : 1,201.76 (+0.20%)
BIIB : 203.30 (-0.76%)
AMGN : 326.93 (+0.05%)
LLY : 954.48 (+0.42%)
VRTX : 480.30 (-0.48%)
3 No-Brainer Stocks to Buy in July

Investors shouldn't have to think too hard about these great stocks.

LLY : 954.48 (+0.42%)
REGN : 1,201.76 (+0.20%)
VRTX : 480.30 (-0.48%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 41.7200 (-0.67%)
ONCY : 0.9672 (-0.18%)
VSTM : 2.47 (-5.36%)
CADL : 5.88 (+0.34%)
FGEN : 0.3851 (-2.51%)
REGN : 1,201.76 (+0.20%)
ONC.TO : 1.30 (-0.76%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 0.9672 (-0.18%)
ONC.TO : 1.30 (-0.76%)
RHHBY : 41.7200 (-0.67%)
VSTM : 2.47 (-5.36%)
CADL : 5.88 (+0.34%)
FGEN : 0.3851 (-2.51%)
REGN : 1,201.76 (+0.20%)
How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

REGN : 1,201.76 (+0.20%)
IBB : 147.87 (-0.01%)
AMGN : 326.93 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 1,216.70
2nd Resistance Point 1,211.76
1st Resistance Point 1,205.56
Last Price 1,201.76
1st Support Level 1,194.42
2nd Support Level 1,189.48
3rd Support Level 1,183.28

See More

52-Week High 1,211.20
Last Price 1,201.76
Fibonacci 61.8% 1,042.35
Fibonacci 50% 990.19
Fibonacci 38.2% 938.04
52-Week Low 769.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar